Newron Pharmaceuticals Spa Stock Current Valuation
| NWRN Stock | CHF 8.41 0.10 1.18% |
Valuation analysis of Newron Pharmaceuticals helps investors to measure Newron Pharmaceuticals' intrinsic value by examining its available valuation indicators, including the cash flow records, the balance sheet account changes and income statement patterns.
Undervalued
Today
Please note that Newron Pharmaceuticals' price fluctuation is somewhat reliable at this time. Calculation of the real value of Newron Pharmaceuticals is based on 3 months time horizon. Increasing Newron Pharmaceuticals' time horizon generally increases the accuracy of value calculation and significantly improves the predictive power of the methodology used.
The fair value of the Newron stock is determined by what a typical buyer is willing to pay for full or partial control of Newron Pharmaceuticals SpA. Since Newron Pharmaceuticals is currently traded on the exchange, buyers and sellers on that exchange determine the market value of Newron Stock. However, Newron Pharmaceuticals' intrinsic value may or may not be the same as its current market price, in which case there is an opportunity to profit from the mispricing, assuming the market price will eventually merge with its intrinsic value. | Historical | Market 8.41 | Real 8.88 | Hype 8.41 |
The intrinsic value of Newron Pharmaceuticals' stock can be calculated using various methods such as discounted cash flow analysis, price-to-earnings ratio, or price-to-book ratio. That value may differ from its current market price, which is determined by supply and demand factors such as investor sentiment, market trends, news, and other external factors that may influence Newron Pharmaceuticals' stock price. It is important to note that the real value of any stock may change over time based on changes in the company's performance.
Estimating the potential upside or downside of Newron Pharmaceuticals SpA helps investors to forecast how Newron stock's addition to their portfolios will impact the overall performance. We also use other valuation drivers to help us estimate the true value of Newron Pharmaceuticals more accurately as focusing exclusively on Newron Pharmaceuticals' fundamentals will not take into account other important factors: Newron Pharmaceuticals SpA Company Current Valuation Analysis
Newron Pharmaceuticals' Enterprise Value is a firm valuation proxy that approximates the current market value of a company. It is typically used to determine the takeover or merger price of a firm. Unlike Market Cap, this measure takes into account the entire liquid asset, outstanding debt, and exotic equity instruments that the company has on its balance sheet. When a takeover occurs, the parent company will have to assume the target company's liabilities but will take possession of all cash and cash equivalents.
Current Newron Pharmaceuticals Current Valuation | 32.84 M |
Most of Newron Pharmaceuticals' fundamental indicators, such as Current Valuation, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Newron Pharmaceuticals SpA is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Enterprise Value can be a useful tool to compare companies with different capital structures. Long term liability and current cash or cash equivalents can have a huge impact on market valuation of a given company.
| Competition |
In accordance with the recently published financial statements, Newron Pharmaceuticals SpA has a Current Valuation of 32.84 M. This is 99.77% lower than that of the Healthcare sector and 99.29% lower than that of the Biotechnology industry. The current valuation for all Switzerland stocks is 99.8% higher than that of the company.
Newron Current Valuation Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Newron Pharmaceuticals' direct or indirect competition against its Current Valuation to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Newron Pharmaceuticals could also be used in its relative valuation, which is a method of valuing Newron Pharmaceuticals by comparing valuation metrics of similar companies.Newron Pharmaceuticals is currently under evaluation in current valuation category among its peers.
Newron Fundamentals
| Return On Equity | -8.4 | |||
| Return On Asset | -0.16 | |||
| Profit Margin | (2.44) % | |||
| Operating Margin | (1.84) % | |||
| Current Valuation | 32.84 M | |||
| Shares Outstanding | 17.85 M | |||
| Shares Owned By Insiders | 4.96 % | |||
| Shares Owned By Institutions | 7.28 % | |||
| Price To Earning | (11.88) X | |||
| Price To Book | 7.98 X | |||
| Price To Sales | 3.95 X | |||
| Revenue | 5.76 M | |||
| Gross Profit | 5.76 M | |||
| EBITDA | (11.76 M) | |||
| Net Income | (14.9 M) | |||
| Cash And Equivalents | 58.99 M | |||
| Cash Per Share | 3.31 X | |||
| Total Debt | 42.93 M | |||
| Debt To Equity | 0.70 % | |||
| Current Ratio | 13.90 X | |||
| Book Value Per Share | (0.29) X | |||
| Cash Flow From Operations | (11.45 M) | |||
| Earnings Per Share | (0.85) X | |||
| Target Price | 4.35 | |||
| Number Of Employees | 25 | |||
| Beta | 1.11 | |||
| Market Capitalization | 81.91 M | |||
| Total Asset | 50.49 M | |||
| Z Score | 0.6 | |||
| Net Asset | 50.49 M |
About Newron Pharmaceuticals Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Newron Pharmaceuticals SpA's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Newron Pharmaceuticals using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Newron Pharmaceuticals SpA based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.| ZLAB | Zai Lab | |
| ASLE | AerSale Corp | |
| ATS | AT S Austria |
Additional Tools for Newron Stock Analysis
When running Newron Pharmaceuticals' price analysis, check to measure Newron Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Newron Pharmaceuticals is operating at the current time. Most of Newron Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Newron Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Newron Pharmaceuticals' price. Additionally, you may evaluate how the addition of Newron Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.